Teva

Teva unveiled Teva Rise, an open innovation platform that connects startups with Teva around technologies including AI, industry 4.0 smart manufacturing, digital health and biotech. The first cohort is a set of challenges for partners, not a statement that those AI systems are already running.

Teva describes ToMoTo, its topic-modeling tool, as artificial intelligence software that searches medical-affairs databases and compiles a report within three to five minutes.

Immunai announced a multi-year collaboration with Teva in immunology and immuno-oncology. Immunai says the work will use its AI model, the Immunodynamics Engine, for clinical-trial decisions including mechanism of action, dose selection and biomarker analyses.

Partners: Immunai

The same Teva article says AI technology can also be used to select clinical trial sites by combining internal and external data to predict site performance.

The same article says it is also possible to run clinical interviews through an avatar operated by AI, with virtual humans and multimodal interaction for assessment.

Teva's chief medical officer says Teva is using AI for digital-biomarker projects that include a facial-recognition tool for tardive dyskinesia diagnosis (extracting ~500 facial landmarks), an automated speech-based tool relating voice parameters to the PANSS scale, and wearable movement sensors correlated with clinical outcomes in multiple system atrophy.

Teva and Biolojic announced an exclusive license to develop a potential antibody therapy for atopic dermatitis and asthma. The release describes Biolojic as a company that uses computational biology and artificial intelligence to design antibodies.

Partners: Biolojic Design

Teva describes AION Labs, the venture studio it formed with AstraZeneca, Merck, Pfizer and other partners, and says DenovAI has developed an AI-physics platform to discover antibodies and proteins for conditions such as cancer and neurodegenerative illness.

Partners: AION Labs